| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
General Counsel
1 company
Todd Christopher Longsworth last filed a Form 4 in March 2022, as General Counsel at NVCR. Todd Christopher Longsworth's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
Our model assigns Todd Christopher Longsworth a below-average insider score of 26/100, based on 3 past trades. Over a 12-month horizon, none of those trades were profitable, with an average 12-month return of -8.2%.
At the last filing, the largest reported position was 62,462 shares of NVCR. The NVCR filings lean toward selling, a net 335,915 shares.
Todd Christopher Longsworth has 30 Form 4 filings on record from February 2017 to March 2022, all as General Counsel at NovoCure (NVCR), 2017–2022.
The 93 reported transactions were 57 open-market sales, 16 option exercises, 10 option or other derivative awards and 10 stock awards.
Counted by filing, the open-market trades come to no purchases and 17 sales worth about $31.1M.
The largest open-market sale was 158,440 shares of NVCR at an average $87.87 on September 3, 2019, about $13.9M.
Shares as reported in the last Form 4 for each company; the most recent is from March 2022. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 8, 2022 | NVCR Novocure Ltd | General Counsel | Sell | 2,339 | $70.10 | $163,963.90 | -3.6% | +13.2% | +6.5% | |
| Mar 4, 2022 | NVCR Novocure Ltd | General Counsel | Sell | 3,067 | $71.87 | $220,413.82 | -4.5% | +22.4% | +12.5% | |
| Mar 8, 2021 | NVCR Novocure Ltd | General Counsel | Sell | 2,404 | $130.81 | $314,457.62 | -3.4% | - | - | |
| Mar 4, 2021 | NVCR Novocure Ltd | General Counsel | Sell | 3,084 | $137.55 | $424,216.54 | -4.2% | - | - | |
| Mar 2, 2021 | NVCR Novocure Ltd | General Counsel | Sell | 2,355 | $152.05 | $358,084.82 | -3.6% | - | - | |
| Jan 15, 2021 | NVCR Novocure Ltd | General Counsel | Sale+OE | 63,814 | $172.48 | $11,006,647.34 | -51.7% | - | - | |
| Mar 6, 2020 | NVCR Novocure Ltd | General Counsel | Sell | 2,499 | $69.53 | $173,765.47 | -2.8% | - | - | |
| Feb 28, 2020 | NVCR Novocure Ltd | General Counsel | Sale+OE | 2,643 | $72.22 | $190,864.25 | -3.6% | - | - | |
| Feb 25, 2020 | NVCR Novocure Ltd | General Counsel | Sale+OE | 8,482 | $81.16 | $688,365.19 | -11.2% | - | - | |
| Sep 3, 2019 | NVCR Novocure Ltd | General Counsel | Sale+OE | 158,440 | $87.87 | $13,922,589.48 | -74.6% | - | - |